Results Comparison of Cervical Cancer Early Detection Using Cerviray with VIA Test

Objectives This study investigates the performance of Cerviray A.I. and evaluation of Cerviray A.I. by an expert, an artificial intelligence (AI) technology for diagnosing cervical cancer, aiming to compare its sensitivity, specificity, positive predictive value (PPV), and area under the receiver operating characteristic curve (AUC ROC) with the Visual Inspection with Acetic Acid (VIA) test. Results The study involved 44 patients from various health centers in West Java Province. Cerviray A.I., evaluation of Cerviray® A.I. by an expert, and VIA tests were administered to high-risk women of childbearing age. Preliminary results indicated that Cerviray A.I. had a sensitivity of 42.9%, specificity and PPV of 100%, and an AUC ROC of 71.4%. In comparison, the evaluation of Cerviray by an expert demonstrated a sensitivity of 71.4%, specificity of 97.3%, PPV of 83.3%, and AUC ROC of 84.4%. Evaluation of Cerviray A.I. by an expert outperformed Cerviray A.I. in AUC ROC.